SlideShare a Scribd company logo
1 of 2
Download to read offline
Global Access Programs
CaligorRx.com
Providing physicians with access to medicines unavailable in their countries has revolutionized the way
in which pharmaceutical and biotech companies serve patients in need. These programs, called Global
Access Programs (GAP), can be complex given the dynamic regulatory environment, the unpredictability
of requests and the speed at which these medicines need to be delivered to patients. Caligor bridges
the gap between medicines with limited availability and patients in need using our innovative regulato-
ry-compliant programs for drug access. Working alongside your team, we provide strategies to facilitate
optimal access throughout the product life cycle including the delivery of drug to sites into over 100
countries. Caligor GAPs can be implemented during various points in the lifecycle, such as:
• Still in clinical development but having sufficient safety / efficacy data
• As an optimal solution for patients exiting trials and / or in lieu of open label extension studies while
commercializing worldwide
• Where the medicine is licensed in one or more countries, but not in the patient’s country
Caligor GAPs are unique in that they are established on the basis of a clinical trial model but adapted
and customized to reflect the specific needs of an access program. Our approach uses validated clinical
trial e-tools and platforms that sponsors, physicians and sites have come to expect. Our “full-service”
approach allows companies to remain focused on the drug development process while we manage all
aspects of the program.
“With the advent of social media platforms,
global demand for access to medicines
is at an all-time high. Pharmaceutical and
biotechnology companies must be prepared
to respond to physicians and patients. In an
effort to foster an ethical response, positive
publicity and ensure regulatory compliance,
companies may inquire as to what approach
they should take for these programs. Caligor
provides the answers to these questions by
effectively filling the access gap.”
Addressing unmet medical needs of patients
Bridging the GAP
Bridging the GAP
INTERNATIONAL REGULATIONS
PATIENTS NEEDING
MEDICATIONS
MEDICATIONS
WITH LIMITED
ACCESSIBILITY
Global Access Programs
CaligorRx.com
For sponsors, the benefits of Global Access Programs are:
• Controlled access and strong visibility of demand patterns
• First look at “real-world” data
• Fostering of early relationships with physicians, patients and regulators
• Increased product awareness / experience prior to launch
• Potential for revenue stream
Our leadership consists of key individuals with many years of experience in this niche space and who
can strategically unlock the value of your access program. The full service approach allows companies to
“hand off” these critical programs to an expert so they can remain focused on the clinical development
and commercialization efforts. Caligor has implemented the latest e-tools and platforms that sponsors
and physicians recognize, allowing for ease of use and 24/7/365 accessibility. In addition, we only em-
ploy experienced program team members that have clinical trial experience and understand the nuances
of working with global sites, sponsors and their affiliates. Our programs also give visibility to real time
access to your real world data.
Another key to our success in delivering high value GAP medicines to sites around the world is our state
of the art facilities in both the US and the UK, enhanced by our worldwide strategic warehouse depots.
We partner with a range of speciality couriers to ensure there is a high touch element to transporting your
medicines to physicians and patients in need guaranteeing that there are no delays in delivery.
Planning for and establishing an access strategy with Caligor early in the product development cycle
offers companies the ability to understand demand and have the optimal provision and company position
for granting access throughout the lifecycle. By entrusting Caligor to manage your Global Access
Program, you can be assured that your program is being managed by a highly experienced team that
considers themselves an extension of your organization.
For more information about our Global Access Programs, please contact us at:
CaligorGAP@CaligorRx.com
Caligor Rx Ltd.
Unit 23 Schooner Park
Schooner Court
Crossways Business Park
Dartford
Kent
DA2 6NW
United Kingdom
+44 (0) 1322 311 134	
Caligor Rx Inc.
801 Penhorn Avenue
No.4
Secaucus, NJ 07094
USA
+1 212.988.0590
	
BEST-IN-INDUSTRY
LEADERSHIP
UNIQUE
FULL-SERVICE
PARTNER
INNOVATIVE
TECHNOLOGY
SEASONED
PROGRAM MANAGEME NT
TEAM
LEADERSHIP
FULL-SERVICE
TECHNOLOGY
TEAM
Program Success
“Our team understands the critical
importance of strong and effective
relationships with sponsors and
sites, thus we only employ sea-
soned program operations team
members with direct clinical trial
experience.” Caligor is uniquely qualified as your Global Access Program partner based on our
four pillars that support program success.

More Related Content

What's hot

Escalation Point & Stryker
Escalation Point & StrykerEscalation Point & Stryker
Escalation Point & StrykerJordan C. Jones
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCovance
 
Consumer Participation at ReGen (APSAD Conference 2013)
Consumer Participation at ReGen (APSAD Conference 2013)Consumer Participation at ReGen (APSAD Conference 2013)
Consumer Participation at ReGen (APSAD Conference 2013)Uniting ReGen
 
Design and Implementation for HARPC
Design and Implementation for HARPCDesign and Implementation for HARPC
Design and Implementation for HARPCAudioEducator
 
Navigating Pharmacovigilance
Navigating PharmacovigilanceNavigating Pharmacovigilance
Navigating PharmacovigilanceLauren Carr
 
CHRONIC HEPATITIS C TREATMENT EXPANSION
CHRONIC HEPATITIS C TREATMENT EXPANSIONCHRONIC HEPATITIS C TREATMENT EXPANSION
CHRONIC HEPATITIS C TREATMENT EXPANSIONThe ScientifiK
 
FSMA Club: Qualify This! - Preventative Controls Qualified Individual
FSMA Club: Qualify This! - Preventative Controls Qualified IndividualFSMA Club: Qualify This! - Preventative Controls Qualified Individual
FSMA Club: Qualify This! - Preventative Controls Qualified IndividualTraceGains
 
Regulatory Compliance in the Pharmaceutical Supply Chain
Regulatory Compliance in the Pharmaceutical Supply ChainRegulatory Compliance in the Pharmaceutical Supply Chain
Regulatory Compliance in the Pharmaceutical Supply ChainAudioEducator
 
2020 Executive Summary: The Post-COVID Pharma Report by Reuters Events
2020 Executive Summary: The Post-COVID Pharma Report by Reuters Events2020 Executive Summary: The Post-COVID Pharma Report by Reuters Events
2020 Executive Summary: The Post-COVID Pharma Report by Reuters EventsMohamadMeski
 
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Covance
 
Real Staffing Life Science Division Markets
Real Staffing Life Science Division MarketsReal Staffing Life Science Division Markets
Real Staffing Life Science Division MarketsMark AJ Smith
 
Max Neeman International Overview
Max Neeman International OverviewMax Neeman International Overview
Max Neeman International OverviewMNI08072014
 
Introducing Successful and Seamless QPP Achievement through the MiraMed Famil...
Introducing Successful and Seamless QPP Achievement through the MiraMed Famil...Introducing Successful and Seamless QPP Achievement through the MiraMed Famil...
Introducing Successful and Seamless QPP Achievement through the MiraMed Famil...MiraMed: A Global Services Company
 
Chill Out About FSMA - It's Complex, but it's Not Rocket Science
Chill Out About FSMA - It's Complex, but it's Not Rocket ScienceChill Out About FSMA - It's Complex, but it's Not Rocket Science
Chill Out About FSMA - It's Complex, but it's Not Rocket ScienceTraceGains
 

What's hot (19)

Escalation Point & Stryker
Escalation Point & StrykerEscalation Point & Stryker
Escalation Point & Stryker
 
Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...
Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...
Session 1 - Mark Paxton, US FDA / APEC Roadmap to Promote Global Medical Prod...
 
Cell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise SolutionsCell & Gene Therapy Enterprise Solutions
Cell & Gene Therapy Enterprise Solutions
 
Consumer Participation at ReGen (APSAD Conference 2013)
Consumer Participation at ReGen (APSAD Conference 2013)Consumer Participation at ReGen (APSAD Conference 2013)
Consumer Participation at ReGen (APSAD Conference 2013)
 
Design and Implementation for HARPC
Design and Implementation for HARPCDesign and Implementation for HARPC
Design and Implementation for HARPC
 
Navigating Pharmacovigilance
Navigating PharmacovigilanceNavigating Pharmacovigilance
Navigating Pharmacovigilance
 
Ashfield Pharmacovigilance
Ashfield PharmacovigilanceAshfield Pharmacovigilance
Ashfield Pharmacovigilance
 
CHRONIC HEPATITIS C TREATMENT EXPANSION
CHRONIC HEPATITIS C TREATMENT EXPANSIONCHRONIC HEPATITIS C TREATMENT EXPANSION
CHRONIC HEPATITIS C TREATMENT EXPANSION
 
FSMA Club: Qualify This! - Preventative Controls Qualified Individual
FSMA Club: Qualify This! - Preventative Controls Qualified IndividualFSMA Club: Qualify This! - Preventative Controls Qualified Individual
FSMA Club: Qualify This! - Preventative Controls Qualified Individual
 
Private Label Management Programs
Private Label Management ProgramsPrivate Label Management Programs
Private Label Management Programs
 
Regulatory Compliance in the Pharmaceutical Supply Chain
Regulatory Compliance in the Pharmaceutical Supply ChainRegulatory Compliance in the Pharmaceutical Supply Chain
Regulatory Compliance in the Pharmaceutical Supply Chain
 
2020 Executive Summary: The Post-COVID Pharma Report by Reuters Events
2020 Executive Summary: The Post-COVID Pharma Report by Reuters Events2020 Executive Summary: The Post-COVID Pharma Report by Reuters Events
2020 Executive Summary: The Post-COVID Pharma Report by Reuters Events
 
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
Field Services: Providing On-Site, Field-Based Assistance to Support Customer...
 
Real Staffing Life Science Division Markets
Real Staffing Life Science Division MarketsReal Staffing Life Science Division Markets
Real Staffing Life Science Division Markets
 
Max Neeman International Overview
Max Neeman International OverviewMax Neeman International Overview
Max Neeman International Overview
 
Introducing Successful and Seamless QPP Achievement through the MiraMed Famil...
Introducing Successful and Seamless QPP Achievement through the MiraMed Famil...Introducing Successful and Seamless QPP Achievement through the MiraMed Famil...
Introducing Successful and Seamless QPP Achievement through the MiraMed Famil...
 
Chill Out About FSMA - It's Complex, but it's Not Rocket Science
Chill Out About FSMA - It's Complex, but it's Not Rocket ScienceChill Out About FSMA - It's Complex, but it's Not Rocket Science
Chill Out About FSMA - It's Complex, but it's Not Rocket Science
 
PC15218_preview
PC15218_previewPC15218_preview
PC15218_preview
 
Navicor Capabilities
Navicor Capabilities Navicor Capabilities
Navicor Capabilities
 

Similar to Caligor_GAP_April_2015

The Hub – Solutions Distinctly for Nimble Biotechs Brochure
The Hub – Solutions Distinctly for Nimble Biotechs Brochure The Hub – Solutions Distinctly for Nimble Biotechs Brochure
The Hub – Solutions Distinctly for Nimble Biotechs Brochure Covance
 
Readying Your Science for the Real World
Readying Your Science for the Real WorldReadying Your Science for the Real World
Readying Your Science for the Real WorldNoel Alaka
 
Delivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and valueDelivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and valueKishan Patel, MBA
 
Fulgent Genetics - Biotech - Total return >200%
Fulgent Genetics - Biotech - Total return >200%Fulgent Genetics - Biotech - Total return >200%
Fulgent Genetics - Biotech - Total return >200%Rogelio Rea
 
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...TransCelerate
 
Final Slide Show - Ready for EquityNet
Final Slide Show - Ready for EquityNetFinal Slide Show - Ready for EquityNet
Final Slide Show - Ready for EquityNetThomas L. Tucker
 
Customized Oncology Development Solutions: Clinical Trials Designed Around You®
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Customized Oncology Development Solutions: Clinical Trials Designed Around You®
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Covance
 
Sage ERP X3: Improving Transparency In Food Manufacturing
Sage ERP X3: Improving Transparency In Food Manufacturing Sage ERP X3: Improving Transparency In Food Manufacturing
Sage ERP X3: Improving Transparency In Food Manufacturing TGO Consulting
 
Reat Agri Foods Brrochure
Reat Agri Foods BrrochureReat Agri Foods Brrochure
Reat Agri Foods BrrochureChris Reno
 
PAREXEL BioPharm Unit
PAREXEL BioPharm UnitPAREXEL BioPharm Unit
PAREXEL BioPharm UnitNeil Butera
 
Clinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - PepgraClinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - PepgraPEPGRA Healthcare
 
Our POV on Launch Excellence
Our POV on Launch ExcellenceOur POV on Launch Excellence
Our POV on Launch ExcellenceIndegene
 
4.Out sourcing BA&BE to CRO
4.Out sourcing BA&BE to CRO4.Out sourcing BA&BE to CRO
4.Out sourcing BA&BE to CROKrishnapriyaVH1
 
Development and Co-Commercialization for Emerging Biotech organizations
Development and Co-Commercialization for Emerging Biotech organizationsDevelopment and Co-Commercialization for Emerging Biotech organizations
Development and Co-Commercialization for Emerging Biotech organizationsIndegene
 
CopyofAlisonKocandaResumeIL8-3.doc
CopyofAlisonKocandaResumeIL8-3.docCopyofAlisonKocandaResumeIL8-3.doc
CopyofAlisonKocandaResumeIL8-3.docAlison Kocanda, MPH
 
Health management
Health managementHealth management
Health managementNida Naeem
 
Tbi Bioprocessing Services Sept 25.08
Tbi Bioprocessing Services Sept 25.08Tbi Bioprocessing Services Sept 25.08
Tbi Bioprocessing Services Sept 25.08Thomas Wellner
 

Similar to Caligor_GAP_April_2015 (20)

The Hub – Solutions Distinctly for Nimble Biotechs Brochure
The Hub – Solutions Distinctly for Nimble Biotechs Brochure The Hub – Solutions Distinctly for Nimble Biotechs Brochure
The Hub – Solutions Distinctly for Nimble Biotechs Brochure
 
Readying Your Science for the Real World
Readying Your Science for the Real WorldReadying Your Science for the Real World
Readying Your Science for the Real World
 
Delivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and valueDelivering real world evidence to demonstrate product safety and value
Delivering real world evidence to demonstrate product safety and value
 
GALT Presentation
GALT PresentationGALT Presentation
GALT Presentation
 
Fulgent Genetics - Biotech - Total return >200%
Fulgent Genetics - Biotech - Total return >200%Fulgent Genetics - Biotech - Total return >200%
Fulgent Genetics - Biotech - Total return >200%
 
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
 
Final Slide Show - Ready for EquityNet
Final Slide Show - Ready for EquityNetFinal Slide Show - Ready for EquityNet
Final Slide Show - Ready for EquityNet
 
Customized Oncology Development Solutions: Clinical Trials Designed Around You®
Customized Oncology Development Solutions: Clinical Trials Designed Around You®Customized Oncology Development Solutions: Clinical Trials Designed Around You®
Customized Oncology Development Solutions: Clinical Trials Designed Around You®
 
QIAGEN - Press release
QIAGEN - Press releaseQIAGEN - Press release
QIAGEN - Press release
 
Sage ERP X3: Improving Transparency In Food Manufacturing
Sage ERP X3: Improving Transparency In Food Manufacturing Sage ERP X3: Improving Transparency In Food Manufacturing
Sage ERP X3: Improving Transparency In Food Manufacturing
 
Reat Agri Foods Brrochure
Reat Agri Foods BrrochureReat Agri Foods Brrochure
Reat Agri Foods Brrochure
 
PAREXEL BioPharm Unit
PAREXEL BioPharm UnitPAREXEL BioPharm Unit
PAREXEL BioPharm Unit
 
Clinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - PepgraClinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - Pepgra
 
Our POV on Launch Excellence
Our POV on Launch ExcellenceOur POV on Launch Excellence
Our POV on Launch Excellence
 
4.Out sourcing BA&BE to CRO
4.Out sourcing BA&BE to CRO4.Out sourcing BA&BE to CRO
4.Out sourcing BA&BE to CRO
 
Development and Co-Commercialization for Emerging Biotech organizations
Development and Co-Commercialization for Emerging Biotech organizationsDevelopment and Co-Commercialization for Emerging Biotech organizations
Development and Co-Commercialization for Emerging Biotech organizations
 
CopyofAlisonKocandaResumeIL8-3.doc
CopyofAlisonKocandaResumeIL8-3.docCopyofAlisonKocandaResumeIL8-3.doc
CopyofAlisonKocandaResumeIL8-3.doc
 
Health management
Health managementHealth management
Health management
 
Stabicon Corporate Presentation
Stabicon Corporate PresentationStabicon Corporate Presentation
Stabicon Corporate Presentation
 
Tbi Bioprocessing Services Sept 25.08
Tbi Bioprocessing Services Sept 25.08Tbi Bioprocessing Services Sept 25.08
Tbi Bioprocessing Services Sept 25.08
 

Caligor_GAP_April_2015

  • 1. Global Access Programs CaligorRx.com Providing physicians with access to medicines unavailable in their countries has revolutionized the way in which pharmaceutical and biotech companies serve patients in need. These programs, called Global Access Programs (GAP), can be complex given the dynamic regulatory environment, the unpredictability of requests and the speed at which these medicines need to be delivered to patients. Caligor bridges the gap between medicines with limited availability and patients in need using our innovative regulato- ry-compliant programs for drug access. Working alongside your team, we provide strategies to facilitate optimal access throughout the product life cycle including the delivery of drug to sites into over 100 countries. Caligor GAPs can be implemented during various points in the lifecycle, such as: • Still in clinical development but having sufficient safety / efficacy data • As an optimal solution for patients exiting trials and / or in lieu of open label extension studies while commercializing worldwide • Where the medicine is licensed in one or more countries, but not in the patient’s country Caligor GAPs are unique in that they are established on the basis of a clinical trial model but adapted and customized to reflect the specific needs of an access program. Our approach uses validated clinical trial e-tools and platforms that sponsors, physicians and sites have come to expect. Our “full-service” approach allows companies to remain focused on the drug development process while we manage all aspects of the program. “With the advent of social media platforms, global demand for access to medicines is at an all-time high. Pharmaceutical and biotechnology companies must be prepared to respond to physicians and patients. In an effort to foster an ethical response, positive publicity and ensure regulatory compliance, companies may inquire as to what approach they should take for these programs. Caligor provides the answers to these questions by effectively filling the access gap.” Addressing unmet medical needs of patients Bridging the GAP Bridging the GAP INTERNATIONAL REGULATIONS PATIENTS NEEDING MEDICATIONS MEDICATIONS WITH LIMITED ACCESSIBILITY
  • 2. Global Access Programs CaligorRx.com For sponsors, the benefits of Global Access Programs are: • Controlled access and strong visibility of demand patterns • First look at “real-world” data • Fostering of early relationships with physicians, patients and regulators • Increased product awareness / experience prior to launch • Potential for revenue stream Our leadership consists of key individuals with many years of experience in this niche space and who can strategically unlock the value of your access program. The full service approach allows companies to “hand off” these critical programs to an expert so they can remain focused on the clinical development and commercialization efforts. Caligor has implemented the latest e-tools and platforms that sponsors and physicians recognize, allowing for ease of use and 24/7/365 accessibility. In addition, we only em- ploy experienced program team members that have clinical trial experience and understand the nuances of working with global sites, sponsors and their affiliates. Our programs also give visibility to real time access to your real world data. Another key to our success in delivering high value GAP medicines to sites around the world is our state of the art facilities in both the US and the UK, enhanced by our worldwide strategic warehouse depots. We partner with a range of speciality couriers to ensure there is a high touch element to transporting your medicines to physicians and patients in need guaranteeing that there are no delays in delivery. Planning for and establishing an access strategy with Caligor early in the product development cycle offers companies the ability to understand demand and have the optimal provision and company position for granting access throughout the lifecycle. By entrusting Caligor to manage your Global Access Program, you can be assured that your program is being managed by a highly experienced team that considers themselves an extension of your organization. For more information about our Global Access Programs, please contact us at: CaligorGAP@CaligorRx.com Caligor Rx Ltd. Unit 23 Schooner Park Schooner Court Crossways Business Park Dartford Kent DA2 6NW United Kingdom +44 (0) 1322 311 134 Caligor Rx Inc. 801 Penhorn Avenue No.4 Secaucus, NJ 07094 USA +1 212.988.0590 BEST-IN-INDUSTRY LEADERSHIP UNIQUE FULL-SERVICE PARTNER INNOVATIVE TECHNOLOGY SEASONED PROGRAM MANAGEME NT TEAM LEADERSHIP FULL-SERVICE TECHNOLOGY TEAM Program Success “Our team understands the critical importance of strong and effective relationships with sponsors and sites, thus we only employ sea- soned program operations team members with direct clinical trial experience.” Caligor is uniquely qualified as your Global Access Program partner based on our four pillars that support program success.